To determine whether improved immune function could enhance the endogenous CD8+ T cell response to AML challenge post-BMT, congeneic BMT recipients were vaccinated with DC/CCL21 or DC/null pre-loaded with AML (C1498 cell) lysates. The gene discussed is CD8A; the disease is acute myeloid leukemia.